Key takeaways:
Immunotherapy medications help your immune system be better at fighting cancer.
Different tests are available that help offer insight into immunotherapy’s effectiveness.
Like other cancer treatments, immunotherapy causes side effects that are different for everyone.
Your immune system is a critical part of your body's defenses. One of its main jobs is to prevent and fight infections caused by viruses, bacteria, and fungi. Without a functioning immune system, it's possible to develop serious health complications.
Aside from protecting against infections, your immune system can also help fight cancer. But, sometimes, it needs help. Many immunotherapy medications have been researched and approved to help your immune system target and fight cancer cells.
Immunotherapy can often help people with cancer live longer compared to traditional treatments like chemotherapy and radiation. But after you start receiving it, you often don't feel noticeably better or different. So, how do you know if these medications are working?
Here, we’ll discuss how to tell if immunotherapy is working, its effectiveness, and its potential side effects.
A positive response to immunotherapy is measured by how your cancer improves over time. If it stays the same, gets smaller, or becomes more controlled, that's ideal.
Your healthcare provider will be in charge of monitoring this progression. They often use physical exams, imaging tests, and blood tests to measure how a cancer responds to treatment.
Measuring a tumor's response to immunotherapy can be difficult. Blood tests can help in diagnosing and monitoring some types of cancer, but they don’t always show how well immunotherapy is working.
These types of blood tests usually involve looking for biomarkers. They’re types of natural markers, or signs, that are found in body fluids and tissues throughout the body.
Different blood tests are available that can look for these biomarkers. Some biomarkers are helpful in identifying cancer or when deciding if a certain treatment option may be effective. For example, the FDA has approved a number of blood tests to identify genetic mutations that can predict if people will respond well to immunotherapies.
Separately, it’s thought that some biomarkers could help monitor how well a particular treatment may be working over time. But, as of right now, there aren’t any blood tests that are FDA approved or authorized to measure how well immunotherapy is working.
Most likely.
For example, the Cancer Research Institute and the Mark Foundation for Cancer Research are researching a biomarker-directed blood test. This study aims to assess how well a biomarker blood test tracks the response of a type of lung cancer (NSCLC) to immunotherapy.
Another study is investigating whether a type of liquid biopsy (ctDNA) can detect a response to immunotherapy faster than other imaging tools. Other results so far in this field are promising.
Sadly, there’s not a straightforward answer for this. How long you have to be on immunotherapy depends on several different factors:
The type and severity of your cancer
The type of immunotherapy you're prescribed
How your cancer responds to immunotherapy
If you’re curious how long you might have to take immunotherapy for, talk to your cancer specialist. They may be able to provide more information based on your situation.
Immunotherapy treatments usually take longer to show signs of tumor reduction than traditional treatments like chemotherapy and radiation.
Chemotherapy works by attacking fast-dividing cancer cells. When people respond to chemotherapy, the treatment starts to work quickly.
Immunotherapy helps activate your immune system to better find and destroy cancer cells. But by comparison, people usually experience a delayed response to immunotherapy. It doesn’t usually work as fast as chemotherapy.
But there's an upside. Immunotherapy may take more time to start working, but the effects often last longer than traditional treatments.
Immunotherapy is effective for many people that don’t respond well to traditional cancer treatments.
Yet, there are many immunotherapy medications. Effectiveness can vary by medication and cancer type.
For example, immune checkpoint inhibitors like pembrolizumab (Keytruda) have long-term benefits for people with melanoma, squamous cell carcinoma (SCC), and Hodgkin's lymphoma. CAR T-cell therapy is effective for acute lymphocytic leukemia (ALL) with high remission rates.
But, sadly, immunotherapy doesn't work for everyone.
For example, immune checkpoint inhibitors work well for the cancers mentioned above, but very few people with ovarian or pancreatic cancer benefit from these medications. CAR T-cell therapy hasn’t been well studied to treat solid tumors, including breast and brain cancers. Use in such cancers hasn’t proven effective yet.
In general, if you feel worse and tests show your tumor is larger, immunotherapy likely isn't working. If you're concerned about your treatment's effectiveness, please speak with your cancer specialist.
Like with all medications, people can experience side effects from immunotherapy. The side effects you feel will vary depending on your medical history, cancer type, and other medications you’re receiving.
But some side effects are common across most immunotherapy medications. They can occur during and after treatment. Side effects can include:
Flu-like symptoms, such as chills, fever, fatigue, or weakness
Injection-site reactions, like rash, soreness, or swelling
Fast or irregular heartbeat
Retaining water (e.g., swelling, weight gain)
Higher risk of infection
Keep in mind that some immunotherapy medications may carry risks for more serious side effects than others. If you have any bothersome symptoms, let your cancer specialist know as soon as you can.
Immunotherapy is a cancer treatment that offers potential benefits over treatments like chemotherapy and radiation. In some cases, immunotherapy helps people live longer after a cancer diagnosis.
Immunotherapy is effective for many people, but it's important to remember that it doesn't work for all types of cancer. Although immunotherapy treatment offers hope in improving how we treat cancer, we're still in the early stages of understanding how to use these medications to their full potential.
American Academy of Dermatology Association. (2021). Skin Cancer Types: Squamous Cell Carcinoma Overview.
American Cancer Society. (2018). What is Acute Lymphocytic Leukemia (ALL)?
American Cancer Society. (2019). If Cancer Treatments Stop Working.
American Cancer Society. (2021). Immunotherapy for Breast Cancer.
Anagnostou, V., et al. (2019). Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Research.
Amjad, M.T., et al. (2021). Cancer Chemotherapy. StatsPearls.
Bettegowda, C., et al. (2014). Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine.
Borcoman, E., et al. (2018). Patterns of Response and Progression to Immunotherapy. American Society of Clinical Oncology Educational Book.
Cancer Research Institute. (2021). Blood Tests and Immunotherapy: New Approaches to Diagnosing and Treating Cancer Patients.
Chang, S. (2014). Monitoring the Immune Competence of Cancer Patients to Predict Outcome. Cancer Immunology, Immunotherapy.
Esfahani, K., et al. (2020). A review of cancer immunotherapy: from the past, to the present, to the future. Current Oncology.
National Cancer Institute. (2017). Liquid Biopsy: Using DNA in Blood to Detect, Track, and Treat Cancer.
National Cancer Institute. (2019). How Cancer is Diagnosed.
National Cancer Institute. (2019). Immune Checkpoint Inhibitors.
National Cancer Institute. (2019). Immunotherapy Side Effects.
National Cancer Institute. (2019). Immunotherapy to Treat Cancer.
National Cancer Institute. (2020). T-cell Transfer Therapy.
National Cancer Institute. (2021). Biomarker Testing for Cancer Treatment.
National Cancer Institute. (2021). Biomarker.
National Cancer Institute. (2021). Drug resistance.
National Cancer Institute. (2021). Immune system.
National Cancer Institute. (2021). Tumor microenvironment.
National Library of Medicine (US). (2021). Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with NSCLC.
Sambi, M., et al. (2019). Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates. Journal of Oncology.
Shahid, K., et al. (2019). Immunotherapy and targeted therapy-the new roadmap in cancer treatment. Annals of Translational Medicine.
Thursby, E., et al. (2017). Introduction to the human gut microbiota. Biochemical Journal.
Ventola, C.L. (2017). Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations. Pharmacy & Therapeutics.